Pharmaceuticals, Biotechnology and Life Sciences
Camurus will start with the Phase 3 study of once-monthly octreotide subcutaneous depot for treatment of acromegaly CAM2029.
Horizon Therapeutics plc (Nasdaq: HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a strategy to increase the durability of response for patients living with chronic gout refractory to conventional therapies – also known as uncontrolled gout.
SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vaxart, Inc. (NASDAQ: VXRT), a clinical stage biotechnology company developing oral recombinant vaccines that are administered…
Swedish biotech company focused on autoimmune diseases, Cyxone is testing its drug candidate T20K, its first-in-human, phase I, clinical trial, for the treatment of multiple sclerosis (MS).
AstraZeneca’s Bevespi Aerosphere has been approved by the Japanese Ministry of Health, Labour and Welfare for patients with chronic obstructive pulmonary disease, becoming the first approved fixed-dose, long-acting dual bronchodilator in a pressurised metered-dose inhaler device in Japan.
Robert Forrester Stepping Down From His Roles as President and Chief Executive Officer Chief Operating Officer, Dan Paterson Appointed President…
HENDERSON, Nev.–(BUSINESS WIRE)–Spectrum Pharmaceuticals, Inc. (NASDAQ-GS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today the…
-$MRK #MRK–At a meeting with the investment community today, Merck (NYSE: MRK), known as MSD outside the United States and Canada, will outline how its science-led strategy and broad pipeline of promising transformative therapies and vaccines will position the company to deliver strong growth and shareholder value over the long term.
DUBLIN–(BUSINESS WIRE)–The “Psoriasis Market and Forecast Analysis to 2025” drug pipelines has been added to ResearchAndMarkets.com’s offering. Psoriasis is a…
DUBLIN–(BUSINESS WIRE)–The “Global Immunotherapy Drugs Market – Drivers, Restraints, Opportunities, Trends, and Forecast up to 2025” report has been added…